Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Lidocaine in Minimal Invasive Parathyroid Surgery
NCT00528502Phase 3Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2006
- Primary completion
- Jan 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of lidocaine in parathyroid disease (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Severity of Airway Interruption and Quality of Operative Field. Planned start Jun 2006; status: withdrawn.
02
Drugs
lidocaine
03
Conditions
parathyroid disease
Beyond the preview
Go deeper on NCT00528502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00528502.